Clinical Trial Update: Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating zanubrutinib for relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Chen Miao | Conditions: Warm Autoimmune Hemolytic Anemia | Phase 2 | Status: RECRUITING